全身性氟喹诺酮类使用与葡萄膜炎或视网膜脱离风险
该队列研究利用英国两个初级保健数据库关联住院数据,纳入1997年4月至2019年12月间接受氟喹诺酮或头孢菌素处方的成人,并在自我对照病例系列中分析葡萄膜炎或视网膜脱离患者。结果显示氟喹诺酮与头孢菌素相比,葡萄膜炎和视网膜脱离的风险均未达统计学显著升高,自我对照分析中仅30至59天暴露的葡萄膜炎风险比达边界显著。结论认为这些发现不支持全身性氟喹诺酮使用与葡萄膜炎或视网膜脱离风险实质性增加相关。
要点
- 队列研究中氟喹诺酮vs头孢菌素,首次治疗葡萄膜炎aHR 0.91(95%CI 0.72-1.14),所有治疗aHR 1.07(95%CI 0.92-1.25)。
- 队列研究中视网膜脱离首次治疗aHR 1.37(95%CI 0.80-2.36),所有治疗aHR 1.18(95%CI 0.84-1.65)。
- 自我对照病例系列中,仅30至59天暴露的葡萄膜炎aRR 1.16(95%CI 1.00-1.34)达边界显著,其余暴露窗口均未达统计学显著。
核心结论
- 这些发现不支持全身性氟喹诺酮使用与葡萄膜炎或视网膜脱离风险实质性增加相关。
- 尽管不能完全排除关联,但这些发现表明任何绝对风险的增加都会很小,因此临床重要性有限。
研究设计与样本
- 这项队列研究使用临床实践研究数据链Aurum和GOLD英国初级保健记录数据库,并关联住院数据。
- 纳入1997年4月至2019年12月间接受氟喹诺酮或对照抗生素头孢菌素处方的成人。
- 患有葡萄膜炎或视网膜脱离的成人在单独的自我对照病例系列中分析。
- 数据分析于2022年5月至2023年5月进行。
主要发现
- 队列研究共纳入Aurum数据库3 001 256人(1 893 561名女性[63.1%];中位[IQR]年龄51[35-68]岁)和GOLD数据库434 754人(276 259名女性[63.5%];中位[IQR]年龄53[37-70]岁)。
- 葡萄膜炎:氟喹诺酮vs头孢菌素的汇总aHR在首次治疗为0.91(95%CI 0.72-1.14),在所有治疗为1.07(95%CI 0.92-1.25)。
- 视网膜脱离:汇总aHR在首次治疗为1.37(95%CI 0.80-2.36),在所有治疗为1.18(95%CI 0.84-1.65)。
- 自我对照病例系列中,葡萄膜炎:氟喹诺酮使用vs不使用的汇总aRR在暴露1至29天为1.13(95%CI 0.97-1.31),30至59天为1.16(95%CI 1.00-1.34),60天及以上为0.98(95%CI 0.74-1.31)。
- 视网膜脱离:汇总aRR在暴露1至29天为1.15(95%CI 0.86-1.54),30至59天为0.94(95%CI 0.69-1.30),60天及以上为1.03(95%CI 0.59-1.78)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Fluoroquinolone use has been associated with increased risk of uveitis and retinal detachment in noninterventional studies, but the findings have been conflicting and causality is unclear. OBJECTIVE: To estimate the association of systemic fluoroquinolone use with acute uveitis or retinal detachment, using multiple analyses and multiple databases to increase the robustness of results. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the Clinical Practice Research Datalink Aurum and GOLD UK primary care records databases, which were linked to hospital admissions data. Adults prescribed a fluoroquinolone or a comparator antibiotic, cephalosporin, between April 1997 and December 2019 were included. Adults with uveitis or retinal detachment were analyzed in a separate self-controlled case series. Data analysis was performed from May 2022 to May 2023. EXPOSURES: Systemic fluoroquinolone or comparator antibiotic. MAIN OUTCOMES AND MEASURES: The primary outcome was a diagnosis of acute uveitis or retinal detachment. Hazard ratios (HRs) were estimated in the cohort study for the association of fluoroquinolone prescription with either uveitis or retinal detachment, using stabilized inverse probability of treatment weighted Cox regression. Rate ratios (RRs) were estimated in the self-controlled case series, using conditional Poisson regression. Estimates were pooled across databases using fixed-effects meta-analysis. RESULTS: In total, 3 001 256 individuals in Aurum (1 893 561 women [63.1%]; median [IQR] age, 51 [35-68] years) and 434 754 in GOLD (276 259 women [63.5%]; median [IQR] age, 53 [37-70] years) were included in the cohort study. For uveitis, the pooled adjusted HRs (aHRs) for use of fluoroquinolone vs cephalosporin were 0.91 (95% CI, 0.72-1.14) at first treatment episode and 1.07 (95% CI, 0.92-1.25) over all treatment episodes. For retinal detachment, the pooled aHRs were 1.37 (95% CI, 0.80-2.36) at first treatment episode and 1.18 (95% CI, 0.84-1.65) over all treatment episodes. In the self-controlled case series, for uveitis, the pooled adjusted RRs (aRRs) for fluoroquinolone use vs nonuse were 1.13 (95% CI, 0.97-1.31) for 1 to 29 days of exposure, 1.16 (95% CI, 1.00-1.34) for 30 to 59 days, and 0.98 (95% CI, 0.74-1.31) for 60 days for longer. For retinal detachment, pooled aRRs for fluoroquinolone use vs nonuse were 1.15 (95% CI, 0.86-1.54) for 1 to 29 days of exposure, 0.94 (95% CI, 0.69-1.30) for 30 to 59 days, and 1.03 (95% CI, 0.59-1.78) for 60 days or longer. CONCLUSIONS AND RELEVANCE: These findings do not support an association of systemic fluoroquinolone use with substantively increased risk of uveitis or retinal detachment. Although an association cannot be completely ruled out, these findings indicate that any absolute increase in risk would be small and, hence, of limited clinical importance.
引用
- Brown JP, Wing K, Evans SJ, et al. Systemic Fluoroquinolone Use and Risk of Uveitis or Retinal Detachment. JAMA Ophthalmol. 2024. PMID: 38814618. doi:10.1001/jamaophthalmol.2024.1712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。